Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

3.8%

2 terminated out of 53 trials

Success Rate

90.0%

+3.5% vs benchmark

Late-Stage Pipeline

8%

4 trials in Phase 3/4

Results Transparency

17%

3 of 18 completed with results

Key Signals

3 with results90% success

Data Visualizations

Phase Distribution

51Total
Not Applicable (3)
Early P 1 (3)
P 1 (22)
P 2 (19)
P 3 (3)
P 4 (1)

Trial Status

Completed18
Unknown15
Recruiting8
Not Yet Recruiting5
Active Not Recruiting4
Terminated2

Trial Success Rate

90.0%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (53)

Showing 20 of 20 trials
NCT04104672Phase 1Active Not RecruitingPrimary

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

NCT05085548Phase 1CompletedPrimary

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

NCT05380414Not ApplicableRecruiting

Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients

NCT06821503Phase 1RecruitingPrimary

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

NCT07006077Phase 2RecruitingPrimary

Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

NCT04469556Phase 2Completed

Pancreatic Adenocarcinoma Signature Stratification for Treatment

NCT07416240Early Phase 1RecruitingPrimary

Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.

NCT04643405Phase 1TerminatedPrimary

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

NCT03889795Phase 1Active Not RecruitingPrimary

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

NCT07138846Phase 3Not Yet RecruitingPrimary

A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer

NCT04098081Phase 2Active Not RecruitingPrimary

1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

NCT07026123Not Yet RecruitingPrimary

A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China

NCT05657418Phase 1TerminatedPrimary

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

NCT04137536Phase 1Active Not Recruiting

A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

NCT06241352Phase 2CompletedPrimary

Statin Addition to Chemotherapy for Advanced Pancreatic Cancer

NCT04796948Phase 1CompletedPrimary

A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

NCT01010945Phase 1CompletedPrimary

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

NCT04228601Phase 1CompletedPrimary

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

NCT03336216Phase 2CompletedPrimary

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

NCT06492941Phase 3Not Yet RecruitingPrimary

A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer

Scroll to load more

Research Network

Activity Timeline